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Isobutene is a high value gaseous alkene used as fuel additive and a chemical building block.
As an alternative to fossil fuel derived isobutene, we here develop a modified mevalonate
pathway for the production of isobutene from glucose in vivo. The final step in the pathway
consists of the decarboxylation of 3-methylcrotonic acid, catalysed by an evolved ferulic acid
decarboxylase (Fdc) enzyme. Fdc belongs to the prFMN-dependent UbiD enzyme family that
catalyses reversible decarboxylation of (hetero)aromatic acids or acrylic acids with extended
conjugation. Following a screen of an Fdc library for inherent 3-methylcrotonic acid dec-
arboxylase activity, directed evolution yields variants with up to an 80-fold increase in
activity. Crystal structures of the evolved variants reveal that changes in the substrate binding
pocket are responsible for increased selectivity. Solution and computational studies suggest
that isobutene cycloelimination is rate limiting and strictly dependent on presence of the
3-methyl group.
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The irrefutable harmful environmental effects and depletingreserves of fossil fuels have powered an extensive amount ofresearch to seek sustainable alternatives for the production
of petrochemicals, including the gaseous alkene isobutene1–3. Due
to the favourable reactivity, isobutene is widely used as a building
block for fuel additives, rubber, plastic and a broad range of fine
chemicals. Over 10 million tons of isobutene are produced every
year, primarily by steam cracking crude oil. Low levels of micro-
bial production of isobutene were first detected in the 1980s4–6.
More recently, isobutene production via a modified mevalonate
(MVA) pathway using mevalonate diphosphate decarboxylase
(MVD) to decarboxylate 3-hydroxyisovaleric acid was reported7
and subsequently patented8 (Fig. 1A). Further studies highlighted
a more efficient route using mevalonate-3-kinase (M3K, Picro-
philus torridus) that catalyses isobutene formation through an
unstable phosphorylated intermediate9,10. The highest reported
whole-cell isobutene production rate of 507 pmol min−1 g cells−1
was reached using E. coli engineered with M3K, however, this
remains about 105-fold lower than is economically viable7,9. The
slow conversion could be surpassed by an alternative route, such
as the more direct conversion of methylcrotonyl-CoA to isobutene
through a combination of a thioesterase with a non-oxidative
decarboxylase. The prenylated flavin (prFMN)-dependent ferulic
acid decarboxylases (Fdc) catalyse reversible non-oxidative (de)
carboxylation of a range of acrylic acids with extended
conjugation11–14. Recently, a reversible 1,3-dipolar cycloaddition
mechanism was conclusively shown to underpin catalysis in
Aspergillus niger Fdc (AnFdc)11,15–17. First, the cycloaddition of
the substrate results in cycloadduct Int1 (Fig. 1B). Decarboxyla-
tion occurs concomitantly with ring opening to form Int2. Fol-
lowing the exchange of CO2 with E282, protonation by E282
results in cycloadduct Int3 that releases the product through
cycloelimination. Cycloadduct strain, mediated by a clash between
the substrate R group and enzyme residues is key in ensuring
reversible 1,3-dipolar cycloaddition17. Recent studies have shown
rational engineering of AnFdc can expand substrate scope to
include aromatic substrates such as naphthoic acid18. Crotonic
acid was found to inhibit AnFdc by apparently irreversibly binding
to the prFMN cofactor17. However, acrylic acid substrates lacking
extended conjugation have rarely been reported in the wider UbiD
enzyme family. Arguably, the natural UbiD substrate closest to
3-methylcrotonic acid is trans-anhydromevalonate 5-phosphate
(tAHMP), which is decarboxylated by a UbiD-decarboxylase
from a hyperthermophilic archaeon Aeropyrum pernix in an
alternative mevalonate pathway19. Both 3-methylcrotonic acid and
tAHMP contain a secondary beta carbon and lack extended
conjugation, however, the phosphate group in tAHMP may
facilitate strain manipulation in cycloadduct intermediates. A
recent communication describes a pathway for the production of
butadiene in E. coli where the decarboxylation of cis,cis-muconic
acid is catalysed by Fdc from Saccharomyces cerevisiae enhanced
by rational design20.
Herein, we report on discovery and optimization through
directed evolution of Fdc decarboxylation activity with
3-methylcrotonic acid to produce isobutene. We seek to under-
stand how a substrate lacking extended conjugation and bulk can
be decarboxylated by Fdc, especially in view of the fact crotonic
acid acts as an inhibitor of prFMN. We discuss the structural
basis for an increase in activity and selectivity in Trichoderma
atroviride Fdc (TaFdc) evolved by directed evolution. Surpris-
ingly, the optimized variants remain unable to decarboxylate
crotonic acid, suggesting that in the case of the substrate
3-methylcrotonic acid the single additional methyl group plays a
key role in the cycloelimination process. Computational studies
are used to rationalize the effect of the 3-methyl substitution on
product formation.
Results and discussion
Initial screening of Fdc homologues. Initial in vivo screening
tested 15 UbiD homologues co-expressed with UbiX (E. coli K-
12) in E. coli for conversion of 3-methylcrotonic acid into iso-
butene as detected by gas chromatography. TaFdc exhibited over































































































Fig. 1 Isobutene production via the modified mevalonate pathway utilizing Fdc for the last step. A Routes to isobutene via modified mevalonate
pathways. Previously published mevalonate diphosphate decarboxylase (MVD)7 and mevalonate-3-kinase (M3K)9 produce isobutene via
3-hydroxyisovaleric acid. Fdc1, co-expressed with UbiX, catalyses the decarboxylation of 3-methylcrotonic acid to give isobutene. B Fdc decarboxylation
reaction mechanism with 3-methylcrotonic acid in blue and common Fdc substrates with a conjugated R-group in red. First, the 1,3-dipolar cycloaddition of
the substrate to prFMNiminium leads to the first pyrrolidine cycloadduct, Int1. Decarboxylation and ring-opening forms the noncyclic alkene adduct Int2.
Protonation by a conserved glutamic acid residue yields the second pyrrolidine cycloadduct Int3 followed by cycloelimination to give the product.
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(Supplementary Table 1) and a directed evolution approach was
taken to generate a variant of TaFdc with superior isobutene
production activity and selectivity for 3-methylcrotonic acid over
cinnamic acid (schematically presented in Supplementary Fig. 1).
TaFdcI, with a T405M mutation, was the first variant with a
considerable increase in isobutene. TaFdcV generated by 4
rounds of evolution has 11 mutations: E25N, N31G, G305A,
D351R, K377H, P402V, F404Y, T405M, T429A, V445P and
Q448W (Table 1).
Characterization of TaFdc and TaFdcV. TaFdc wild-type and
TaFdcV with an N-terminal hexa-histidine tag were co-expressed
with E. coli K-12 UbiX in E. coli and purified with Ni-NTA resin.
UV–Vis spectra of both purified proteins exhibit a distinct peak at
380 nm, thought to correspond to the cofactor active form
prFMNiminium (Supplementary Fig. 2A)16. ESI-MS confirmed the
presence of prFMNiminium in both enzyme variants (Supple-
mentary Fig. 2B and C). The shape of the 380 nm peak and
cofactor content (assessed by the ratio of absorbances at 280 and
380 nm) varied from batch to batch.
TaFdc showed decarboxylation activity with cinnamic and
sorbic acid, with rates kobs= 7.2 ± 0.3 and 3.2 ± 0.3 s−1, respec-
tively (reported for a batch with a 380:280 nm ratio of 0.067).
These values are comparable to those reported for AnFdc11,16. In
contrast, the TaFdcV variant showed compromised activity with
sorbic acid (kobs= 0.33 ± 0.03 s−1) and no activity was detected
with cinnamic acid. When exposed to light, TaFdc sorbic acid
decarboxylation activity steadily deteriorates with a half-life of 1 h
compared to enzyme stored in dark (Supplementary Fig. 2H).
This is consistent with Fdc light-sensitivity as described
previously17. Upon irradiation with a 405 nm LED lamp, the
characteristic 380 nm peak in the UV–visible absorbance spectra
of TaFdc and TaFdcV irreversibly splits to peaks at 365 and
425 nm (Supplementary Fig. 2I and J).
Incubation of both TaFdc and TaFdcV with 3-methylcrotonic
acid triggered a change in the protein UV–Vis spectrum to reveal
peaks at 340 and 425 nm, suggestive of a covalent substrate:prFMN
adduct accumulating under turnover conditions. Following a
desalting step, the spectrum returns to the as-isolated 380 nm
single feature, confirming that a long-lived, inhibitory covalent
complex with 3-methylcrotonic acid is not formed (Supplementary
Fig. 2D and E). Incubation of 80 μmol TaFdcV with 10mM
3-methylcrotonic acid led to a complete shift in the corresponding
UV–Vis spectrum. In contrast, the wild-type TaFdc required
prolonged incubation with 50mM 3-methylcrotonic acid to
achieve full spectral conversion, suggesting a substantially higher
KD and/or adduct formation rate for the wild-type enzyme. An
ESI-MS spectrum of the desalted sample showed peaks corre-
sponding to both prFMNiminium and a putative Int3 prFMN
cycloadduct with 3-methylcrotonic acid (Supplementary Fig. 3).
This may be due to a small proportion of 3-methylcrotonic acid
remains bound to prFMN as Int3, suggesting Int3 elimination is
the rate-limiting step, or that a proportion of the Int3 species has
irreversibly isomerized to a more stable conformation.
In order to assess the scope for activity with acrylic acids
lacking extended conjugation, TaFdc and TaFdcV were incubated
with trans-2-pentenoic and trans-2-hexenoic acid, compounds
that have previously been reported to undergo some AnFdc-
mediated decarboxylation11. UV–Vis absorbance spectra indi-
cated that TaFdc bound both acids (Supplementary Fig. 2F),
whereas the TaFdcV variant preferred the smaller pentenoic acid
and required higher concentrations to fully bind hexenoic acid
(Supplementary Fig. 2G). In contrast to samples incubated with
3-methylcrotonic acid, the UV–Vis spectra of samples incubated
with pentenoic or hexenoic acid were unaffected by a desalting
step, indicating that pentenoic and hexenoic acid irreversibly
binds to TaFdc/TaFdcV. Quantitative GC assay indicates that
pentene production from hexenoic acid by AnFdc is limited to a
single turnover (Supplementary Fig. 4).
Crystal structures of TaFdc and TaFdcV reveal mutation
impact on the substrate-binding pocket. In order to understand
how TaFdcV mutations aid in isobutene production, crystal
structures of TaFdc and TaFdcV were solved at a resolution of
1.74 and 1.89 Å, respectively. An overlay of the wild-type and the
variant crystal structures shows that the key residues F447, Q200
and the catalytic network of E287–R183–E292 are unaffected by
the mutations (Fig. 2A)16. The T405M mutation is located at the
active site, extending towards the space above the prFMN uracil
ring while the Q448W and F404Y mutations are situated in the
second shell from the active site. The E292 residue side chain
occupies ‘up’ and ‘down’ conformations, while weak electron
density suggests a high degree of mobility for the L449 side chain.
The mobile E292 and L449 gate access to the active site (Fig. 2B)
while the Q448W mutation in TaFdcV narrows the binding
pocket (Fig. 2C). The T405M and Q448W mutations are likely to
be responsible for the increased selectivity for 3-methylcrotonic
acid in TaFdcV by enhancing the substrate/active site shape
complementarity, blocking access to larger substrates (Supple-
mentary Fig. 5). While comparison of TaFdc and TaFdcV crystal
structures reveals the basis for increased selectivity in the evolved
enzyme, it is not immediately clear why 3-methylcrotonic acid
can yield isobutene from Int3.
Formation of stable cycloadducts with inhibitors. The effects of
crotonic and 2-butynoic acid on TaFdcV were studied to deter-
mine whether the mutations that increase in 3-methylcrotonic
acid turnover also affected activity with related compounds.
Incubation of TaFdcV with 2-butynoic and crotonic acid led to
the familiar split of the 380 nm prFMN peak in the UV–Vis
spectrum (Fig. 3A and D), similar to 3-methylcrotonic acid.
However, as previously observed with pentenoic and hexenoic
acid, the spectrum did not recover the following desalting, sug-
gesting that a covalent inhibitory adduct is formed. Similar trends
were observed with TaFdc, however, incubation at higher inhi-
bitor concentration was required to drive changes in the UV–Vis
spectrum.
Upon addition of crotonic acid, a gradual shift in UV–Vis
spectrum occurs over minutes, allowing estimation of adduct
formation rate (Supplementary Fig. 6A). The observed rate
remains first order with respect to crotonic acid, with kobs= 0.34
± 0.03 min−1 at the highest concentration tested (50 mM)
Table 1 Summary table of AnFdc and TaFdc variants.
AnFdc AnFdcI AnFdcII TaFdc TaFdcIa TaFdcVa TaFdcII
Mutations WT T395M T395M
R435P P438W
WT T405M E25N N31G G305A D351R K377H P402V





4ZA4 7NF3 7NF4 7NEY No crystal
structure
7NF1 No crystal structure
aProduct of directed evolution.
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(Supplementary Fig. 6B). In contrast, a similar shift in UV–Vis
spectrum upon addition of the substrate 3-methylcrotonic acid
occurs rapidly within seconds, and at substantially lower
3-methylcrotonic acid concentrations. This suggests that crotonic
acid adduct formation is hindered by a higher KD and/or slower
rate of cycloaddition.
ESI–MS and co-crystallization studies confirmed that the
TaFdcV 2-butynoic acid adduct stalls as Int1, while the TaFdcV
crotonic acid adduct undergoes decarboxylation to stall at the
Int3 species (Fig. 3). Similar behaviour has been reported for
AnFdc17. No decarboxylation of the Int1 with 2-butynoic acid
was detected, even in 1-month-old crystals. In contrast, although
only Int3 was observed in co-crystals with crotonic acid, ESI-MS
also showed a peak for the corresponding Int1 (Fig. 3E). It is
unclear whether Int1 can be detected in this case because
decarboxylation of crotonic acid is slow, or because there is an
equilibrium between Int1 and Int3 at ambient CO2 levels.
AnFdcII with three point-mutations has an identical active site
conformation to TaFdcV. To further understand how the
architecture of the active site affects the decarboxylation of
3-methylcrotonic acid, corresponding key mutations from
TaFdcV were introduced in AnFdc. AnFdc has been established
as a model system due to the fact that it readily yields atomic
resolution crystal structures11,16–18. Two variants were studied:
AnFdc T395M (AnFdcI) and the triple mutant AnFdc T395M
R435P P438W (AnFdcII). Overlay of the AnFdc wild-type and
TaFdcV crystal structures reveals a downward shift of the Y404
residue in TaFdcV in the secondary shell compared to the cor-
responding Y394 in AnFdc (Fig. 4A). The Y394 residue is unaf-
fected in the AnFdcI variant compared to wild-type (Fig. 4B). In
contrast, the active site of the AnFdcII variant matches that of
TaFdcV in the conformation of Y394 and M395 (Fig. 4C).
As expected, neither AnFdcI nor AnFdcII were active with
cinnamic acid, likely due to a clash between the substrate phenyl
ring and M395. While binding of crotonic acid in AnFdc wild-
type cannot be detected by the UV–Vis spectra over 2-h
incubation, both mutants AnFdcI and AnFdcII readily bind the
inhibitor, evident from UV–Vis spectra, demonstrating increased
selectivity towards smaller substrates.
TaFdcII has comparable isobutene production activity to
TaFdcV. Selected TaFdc variants (wild-type, TaFdcI i.e. T405M,
TaFdcV, TaFdcII, see Supplementary Fig. 1) and AnFdc variants
(wild-type, AnFdcI, AnFdcII) were purified and assayed for iso-
butene production. TaFdcII (F404Y, T405M, V445P, Q448W)
was created by rational design based on the structural analysis of
TaFdc wild-type, TaFdcV and AnFdcII. A comparison of the
isobutene titre obtained following 2 and 4 h incubation revealed
TaFdcI and AnFdcI produced 4–9 times the amount of isobutene
compared to the wild-type enzymes. Additional mutations in
AnFdcII and TaFdcII led to a substantial further increase of 18
and 81 fold, respectively, in isobutene production (Supplementary
Fig. 7). Surprisingly, the in vitro titer obtained with TaFdcII was
slightly higher than the corresponding TaFdcV levels obtained
(Fig. 5). Thus, the 4 point mutations in TaFdcII (F404Y, T405M,
V445P, Q448W) and 3 point mutations in AnFdcII (T395M,
R435P, P438W), that create an active site architecture identical to
TaFdcV (Fig. 4), appear largely responsible for the increased
isobutene activity compared to wild-type TaFdc and AnFdc.
While AnFdc wild-type was included in the initial UbiD screen,
the AnFdc wild-type was 90 times lower in activity in vivo
compared to TaFdc. Hence, AnFdc was not selected for further
directed evolution, despite having comparable in vitro activity to
TaFdc. The disparate and lower activity in vivo might be
attributed to AnFdc-specific inhibition by metabolites such as



































Fig. 2 Comparison of TaFdc and TaFdcV. A Two views of the overlay of TaFdc wild-type (green, 7NEY [10.2210/pdb7NEY/pdb]) and TaFdcV (blue, 7NF0
[10.2210/pdb7NF0/pdb]) active sites. Comparison of TaFdc B and TaFdcV C binding pockets. The mobile L449 and E292 gate the entrance to the active
site and the Q448W mutation narrows the entrance to the active site.
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production levels using crude cell lysate from cells expressing
TaFdc variants with those expressing MVD and/or M3K reveals a
~50-fold increase is observed for TaFdcV compared to MVD/
M3K levels (Supplementary Fig. 8). This demonstrates that the
evolved TaFdcV is vastly superior in catalysing the decarbox-
ylative step compared to the previously described enzyme
systems.
Computational studies reveal a mechanistic basis for isobutene
production. It is curious that a single methyl group difference, as
occurs between crotonic acid and 3-methylcrotonic acid, deter-
mines whether the compound is a substrate or inhibitor for the
evolved Fdc variants. The marked influence of the additional
methyl group on Int3 cycloelimination suggests this step may
proceed via a cationic or radical beta carbon stabilized through
additional hyperconjugation effects. A density functional theory
(DFT) active site ‘cluster’ model (Supplementary Fig. 9) was used
to investigate why 3-methylcrotonic acid is decarboxylated and
eliminated by TaFdcV in contrast to crotonic acid.
The potential energy surface for the cycloelimination of Int3 to
the non-covalent product complex was computed for both crotonic
acid and 3-methylcrotonic acid by varying the Cα–C1’ and Cβ–C4a
bond lengths (Fig. 6). These suggest that 3-methylcrotonic acid
undergoes a more asynchronous elimination, with the transition
state Cα–C1’ and Cβ–C4a bond lengths of 1.96 and 2.97Å,




















































Fig. 3 Cycloadduct formation in TaFdcV with inhibitors butynoic and crotonic acid. A UV–Vis spectra of TaFdcV before and after incubating with 2-butynoic
acid. B ESI–MS spectra of TaFdcV incubated with 2-butynoic acid and desalted, showing the formation of prFMN-butynoic adduct [M+H]+= 607.18. C Crystal
structure of TaFdcV with prFMN-butynoic adduct (7NF1 [10.2210/pdb7NF1/pdb]). D UV–Vis spectra of TaFdcV as is and incubated with crotonic acid E ESI–MS
spectra of TaFdcV incubated with crotonic acid (and desalted) showing the formation of decarboxylated prFMN-crotonic adduct [M–H]−= 565.21 and traces of











Fig. 4 Comparison of the TaFdcV and AnFdc wild-type and variant active sites. Overlay of TaFdcV (green, 7NEY [10.2210/pdb7NEY/pdb]) with A AnFdc
wild-type (blue, 4ZA4 [10.2210/pdb4ZA4/pdb]), B AnFdcI (blue, 7NF3 [10.2210/pdb7NF3/pdb]) and C AnFdcII (blue, 7NF4 [10.2210/pdb7NF4/pdb])
crystal structures (AnFdc variant residue numbering according to AnFdc).
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respectively. This is linked to an increased charge separation
occurring between the Cβ and prFMN for the 3-methylcrotonic acid
compared to crotonic acid (Supplementary Tables 4 and 5), possibly
affected by additional hyperconjugation in the case of
3-methylcrotonic acid. The release of propene from crotonic acid
Int3 cycloadduct is more endothermic by ~8 kJmol−1 and has a
higher energy barrier by 19 kJmol−1 compared to the release of
isobutene from Int3 with 3-methylcrotonic acid. If the activation
entropy is similar for the two reactions then the transition state
energy difference translates to a ~2200 slower rate for the release of
propene from Int3 at 293K, explaining the lack of crotonic acid
turnover under conditions tested.
The limit of prFMN-dependent (de)carboxylation by UbiD
enzymes. Directed evolution of TaFdc to TaFdcV resulted in a
marked increase in activity with 3-methylcrotonic acid. Surpris-
ingly, the evolved mutant remained unable to convert crotonic
acid to the corresponding propene. This contrasts with previous
evolved studies aimed at expanding the AnFdc substrate reper-
toire to include (hetero)aromatic compounds18. In this case, the
evolution of activity against heteroaromatic bicyclic compounds
yielded a broad specificity variant able to convert even naphthoic
acid. It is thus possible that 3-methylcrotonic acid represents a
limit for bona fide UbiD-substrates, indicating that prFMN-
dependent catalysis requires more than an α,β-unsaturated acrylic
acid (i.e. a secondary Cβ carbon) to yield reversible cycloelimi-
nation. Indeed, crotonic acid readily forms irreversible adducts
with (evolved) Fdc that proceed to the last step prior to product
formation. Detailed studies of the AnFdc mechanism revealed
considerable enzyme-induced strain in substrate-cofactor adducts
that avoid dead-end local energy minima during the covalent
catalysis17. In the case of smaller substrates such as (3-methyl)
crotonic acid, the scope for enzyme-induced strain as a tool to
optimize the energy landscape is minimal. In this case, cycloeli-
mination of isobutene appears feasible at ambient conditions
whereas propene production is not. Computational studies pro-
vide a rationale behind these observations, suggesting a ~2200
fold slower rate for the release of propene from Int3. Thus, fur-
ther optimization of isobutene production and future evolution of
propene producing Fdc variants will need to focus on the ener-
getics of the hydrocarbon elimination step.
Methods
In vivo isobutene assay. In vivo screenings were carried out on a 96-well plate
(DW96, 2.2 mL wells, sealed with a foil sheet). TaFdc and other UbiD homologues
were co-expressed with UbiX (E. coli, K-12) in a petDuet vector (UbiD in MCS1
and UbiX in MCS2) in E. coli (BL21, DE3). Isobutene production from 0.4 mL
reaction mix with 10 mM 3-methylcrotonic acid was detected from the headspace
by gas chromatography. The GC method consisted of 100 µL of headspace with a
split ratio of 10 injected to RTX-1 column (15 m, 0.32 mm internal diameter, 5 µm
film thickness, from RESTEK 10178-111) using nitrogen as a carrier gas (1 mL/min
flow rate). The oven temperature was held at 100 °C and the injector and detector
were maintained at 250 °C. Isobutene was calibrated at 1000, 5000 and 10,000 ppm
with standards from Messer.
Mutagenesis. Point mutations (TaFdcI, TaFdcII, AnFdcI, AnFdcII, Supplemen-
tary Table 6) were generated with a Q5 mutagenesis kit from New England Biolabs.
Primers were designed with NEBaseChanger (New England Biolabs). The presence
of the point mutation was confirmed by sequencing (Eurofins).
Protein expression. A pETDuet-1 vector containing genes for T. atroviride Fdc
(with an N-terminal 6-histidine affinity tag) and UbiX (E. coli, K-12) was trans-
formed into BL21(DE3) competent cells following the manufacturer’s protocol
(Novagen). A colony was inoculated into Lysogeny Broth (supplemented with
100 µg/mL ampicillin) and incubated by shaking overnight at 37 °C. 5 mL of LB
culture was inoculated into 1 L of Terrific Broth (TB, Formedium), supplemented
with 100 µg/mL ampicillin. The culture was incubated by shaking at 37 °C until the
optical density of 0.6–0.8. The cells were induced with 0.4 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and supplemented with 0.5 mM MnCl2. The cultures
were incubated by shaking at 18 °C for 24 h. The cells were harvested by cen-
trifugation (10 min, 8939 × g) and frozen.
Protein purification. Frozen cells were supplemented with EDTA-free protease
inhibitor mixture (Roche Applied Science), lysozyme, DNAse, and RNAse (Sigma)
and resuspended (50 mM HEPES, 300 mM KCl, pH 6.8). The cells were lysed by
sonication on ice (Bandelin Sonoplus sonicator, TT13/F2 tip, 30% power with 20 s
on/40 s off for 15 min) and centrifuged (1 h, 174,000–185,500 × g, Beckman
Optima LE-80k ultracentrifuge, Ti50.2 rotor). The cell-free extract was loaded on
Ni-NTA resin, washed with 4 column volumes of 40 mM imidazole buffer (40 mM
imidazole, 50 mM HEPES, 300 mM KCl, pH 6.8) and eluted in 1 mL fractions with
250 mM imidazole buffer (250 mM imidazole, 50 mM HEPES, 300 mM KCl, pH
6.8). Fractions containing protein were combined and desalted into 25 mM HEPES,
150 mM KCl, pH 6.8. Exposure to light was minimized by covering with foil and
using black Eppendorf tubes.
Cycloadduct formation. TaFdcV (500 µL, 0.45 mM protein, 25 mM HEPES,
150 mM KCl, pH 6.8) was incubated with crotonic or 2-butynoic acid. The for-
mation of the prFMN-crotonic acid cycloadduct was followed by UV–Vis spec-
troscopy and additional acid were added until full conversion (complete loss of the
380 nm peak). The protein was desalted to 25 mM HEPES, 150 mM KCl, pH 6.8
and plated for crystal trials.

















Fig. 5 Isobutene production by TaFdc and AnFdc variants. 3-methylcrotonate decarboxylation assay with purified enzyme comparing isobutene
production as detected by GC by TaFdc and AnFdc variants (Table 1), both with N-terminal His-tags, over 2 and 4 h with 10 mM 3-methylcrotonate and
0.3 mg/mL enzyme. Fold increase comparison is shown in Supplementary Fig. 7. Source data are provided as a Source Data file.
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Crystallization and X-ray structure determination. Crystallization was per-
formed by sitting-drop vapour diffusion. Screening of 0.3 μL of 1 mg/mL TaFdcV
in 25 mM HEPES, 150 mM KCl, pH 6.8, and 0.3 μL of reservoir solution at 4 °C
resulted in a number of hits in the BCS plate from molecular dimensions. Seed
stocks were used to reproduce TaFdc wild-type crystals and co-crystals with
2-butynoic and crotonic acids in the BCS plate. Crystals were cryoprotected with
PEG200 and flash-frozen in liquid nitrogen. AnFdc wild-type and variants were
crystallized in 0.2 M potassium thiocyanate, Bis–Tris propane 6.5, 20% w/v PEG
3350 at 4 °C16. Diffraction data were collected at Diamond beamlines and pro-
cessed using the CCP421 suite version 7.1 (Supplementary Table 7). Phaser MR
version 2.8.3 was used to perform molecular replacement using 4ZA4 [https://
doi.org/10.2210/pdb4ZA4/pdb] as a model. Refinement was carried out with
REFMAC522 and manual rebuilding in COOT23 version 0.9.5. Ligand definitions
and coordinates were generated with AceDRG24.
In vitro isobutene assay comparing TaFdc and AnFdc variants. All variants were
grown in BL21(DE3) cells with a pETDuet plasmid with the Fdc variant (N-terminal
6-His-tag) in the first multiple cloning site and UbiX (untagged, wild-type from E. coli
K12) in second multiple cloning site. The cells were grown in a ZYM-5052 auto-
inducing medium (30 °C for 6 h, followed by 18 °C for 24 h). The Fdc variants were
purified with Protino® Ni-IDA column and stored at−80 °C (in 50mM Tris–HCl pH
7.5, 1mM MnCl2, 20mM NaCl, 200mM KCl, 10% glycerol). Decarboxylation of
3-methylcrotonate was set up in triplicates in 50mM Tris–HCl pH 7.5, 1 mM MnCl2,
20mM NaCl, 200mM KCl with 10mM 3-methylcrotonate and 0.3 mg/mL enzyme
in DW384 plates (40 µL per well, sealed with foil sheet). Isobutene production was
measured from headspace by gas chromatography after 2 and 4 h.
In vitro isobutene assay comparing TaFdc, ScMVD and PtM3K. An equal
amount of E. coli cells containing either empty pETDuet (as control) or one of the
following plasmids: pETDuet TaFdc_UbiX, pETDuet TaFdcV_UbiX, pETDuet
PtM3K (P. torridus mevalonate 3-kinase, Uniprot: Q6KZB1), pETDuet ScMVD (S.
cerevisiae MVD, Uniprot: P32377) or pETDuet PtM3K—ScMVD, were lysed in
50 mM Tris–HCl pH 7.5, 20 mM KCl, 2 mM MgCl2, 1 g/L lysozyme, 0.03 g/L
DNAse for 1 h at 37 °C. A total of 150 μL of lysate was transferred to a 2 mL GC-
vial and MgCl2 (10 mM final concentration) was added. Substrates were added to
50 mM final concentration and 200 μL total volume, and consisted of either 3-
hydroxyisovalerate/ATP, 3-phosphonooxy-isovalerate/ADP or 3-methylcrotonate.
Following 4 h of incubation at either 37 or 50 °C, the reaction mixture was inac-
tivated by incubation at 90 °C for 5 min. GC analysis of the gas phase was carried
out as described above to determine isobutene levels produced. All reactions were
carried out in duplicates.
DFT calculations. TaFdcV active site cluster model with crotonic (365 atoms) and
3-methylcrotonic acid (368 atoms) was built based on the TaFdcV crystal structure
with crotonic acid bound as Int3 adduct (Supplementary Fig. 9) and modelled at
the B3LYP/6–31 G(d,p) level of theory with the D3 version of Grimme’s dispersion
with Becke–Johnson damping and a generic polarizable continuum with ε= 5.7
using the polarizable continuum model25. Cα–C1’ and Cβ–C4a bonds were both
fixed for any single DFT optimization and substrate release was modelled using
Gaussian 09 revision D.01. by lengthening one bond by 0.05 Å at a time, resulting
in a 3D energy landscape consisting of ~900 DFT optimized models (for
3-methylcrotonic acid).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Data supporting the findings of this work are available within the paper and its
Supplementary Information files. A reporting summary for this Article is available as a
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Fig. 6 DFT calculations applied to the active site of TaFdc with 3-methylcrotonic and crotonic acid. Contour map of the potential energy (kJ mol−1)
landscape for 3-methylcrotonic acid (A) and crotonic acid (B) conversion to isobutene and propene, respectively, from Int3 by TaFdcV, projected transition
state is marked by X. C Zero-point energy corrected potential energy (kJ mol−1, Supplementary Tables 2 and 3) scheme for 3-methylcrotonic (red) and
crotonic acid (blue) with the Int3 set as 0 and the projected approximate transition state denoted with double daggers. D overlay of the DFT optimized
transition states between Int3 and product for 3-methylcrotonic (pink, Cα–C1’ and Cβ–C4a bond lengths of 1.96 and 2.97 Å, respectively) and crotonic acid
(blue, Cα–C1’ and Cβ–C4a bond lengths of 1.95 and 2.77 Å, respectively). Source data underlying A–C are provided as a Source Data file.
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study have been deposited in the PDB with the accession codes 7NEY, 7NF0, 7NF1,
7NF2, 7NF3 and 7NF4. Input and output files for DFT calculations are available at
Zenodo [https://doi.org/10.5281/zenodo.5137885]. Source data are provided with
this paper.
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